Background Pediatric cardiac surgery is associated with abnormal coagulation, bleeding,
and nearly ubiquitous transfusions. With the popularization of patient blood management …

BACKGROUND: Prothrombin complex concentrates are an emerging “off-label” therapy to
augment hemostasis after cardiopulmonary bypass (CPB), but data supporting their use for …

Background After decades of practice of pediatric cardiac surgery, postoperative bleeding
due to the immaturity of hemostasis, hemodilution, and hypothermia remains a concern …

Pediatric cardiac surgery patients are predisposed to blood loss. Blood product
administration can lead to complications. Prothrombin complex concentrates (PCCs) offer …

Objective This study aims to compare the efficacy and safety of activated recombinant factor
VII (rFVIIa) and prothrombin complex concentrate (PCC) in the treatment of bleeding …

BACKGROUND: Bleeding is a serious complication after pediatric cardiopulmonary bypass
(CPB) that is associated with an increase in perioperative morbidity and mortality. Four …

Refractory bleeding after cardiopulmonary bypass (CPB) remains a significant problem in
pediatric cardiac surgery. 1, 2 Infants are at great risk for bleeding due to decreased factor …

Various factors may lead to coagulation disturbances following cardiopulmonary bypass and
surgery for congenital heart disease. In addition to the risks associated with the …

The 3-factor prothrombin complex concentrate (3FPCC) may be used off-label to treat
refractory bleeding during cardiac surgery in children. This retrospective study examined the …

Background Bleeding is a common problem in children with congenital heart disease
undergoing major cardiac surgery requiring cardiopulmonary bypass (CPB). Little is known …